Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05356741
Title To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amunix, a Sanofi Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA | ESP | AUS

Facility Status City State Zip Country Details
Investigational site number #100 RECRUITING Melbourne Victoria 3000 Australia Details
Investigational site number #101 RECRUITING Randwick 2031 Australia Details
Investigational site number #150 RECRUITING Toulouse 31059 France Details
Investigational site number #200 RECRUITING Porto 4200-072 Portugal Details
Investigational site number #255 RECRUITING Barcelona 08023 Spain Details
Investigational site number #251 RECRUITING Barcelona 08035 Spain Details
Investigational site number #254 RECRUITING Madrid 28027 Spain Details
Investigational site number #252 RECRUITING Madrid 28050 Spain Details
Investigational site number #250 RECRUITING Pamplona 31008 Spain Details
Investigational site number #253 RECRUITING Pozuelo de Alarcón 28223 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field